Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
AstraZeneca PLC
AZNCF
$204.27 (- $1.18 - 0.57%)
Last updated: Previous Close (2026-04-08)
About the Company
AstraZeneca PLC is a multinational pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It focuses on researching, developing, manufacturing, and commercializing innovative medicines and vaccines across key therapeutic areas including oncology, biopharmaceuticals, cardiovascular, renal, metabolism, respiratory, immunology, rare diseases, and infection. The company maintains major research and development centers in Cambridge, UK; Gaithersburg, Maryland, US; Gothenburg, Sweden; and Warsaw, Poland, supporting a pipeline that addresses cancer, cardiovascular diseases, kidney diseases, influenza, and other conditions. AstraZeneca PLC delivers products for primary care, specialty care, and global health initiatives, with operations spanning innovative medicines and biologics. Its portfolio emphasizes treatments for respiratory inflammation, autoimmune disorders, gastrointestinal issues, neuroscience, and vaccines, contributing to advancements in non-communicable diseases and access programs in various regions worldwide. Founded in 1999, AstraZeneca PLC plays a significant role in the global biopharmaceutical market through its comprehensive therapeutic focus and strategic R&D investments.
Price History
Latest News for AZNCF
Countdown to Astrazeneca (AZN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?
IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.
AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responsesOCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic
AstraZeneca to Report Q4 Earnings: What's in Store for the Stock?
AZN gears up for Q4 results as cancer, diabetes and rare disease drugs drive sales expectations ahead of the Feb. 10 earnings report.
Shell chief exec to become one of FTSE’s best paid bosses
Shell’s chief executive is on course to become one of the best-paid executives on the London Stock Exchange as his company’s move away from green energy pays off.
FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway
AstraZeneca wins FDA priority review for Datroway in triple-negative breast cancer, while Saphnelo SC receives a complete response letter.